Showing results (111-120 of 128) with videos related to

Sort By:
Pageof 13
AIDS (London, England)|April 19, 2000
The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine. Prometheus Study GroupE H Gisolf, S Jurriaans, J Pelgrom, et al.
Blood|July 13, 2000
T-cell progenitor function during progressive human immunodeficiency virus-1 infection and after antiretroviral therapyD R Clark, S Repping, N G Pakker, et al.
The Journal of Infectious Diseases|September 9, 1999
Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1-infected adultsD W Notermans, N G Pakker, D Hamann, et al.
AIDS (London, England)|January 12, 2001
Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infectionM den Brinker, F W Wit, P M Wertheim-van Dillen, et al.
AIDS (London, England)|August 26, 1998
Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapyG J Weverling, J M Lange, S Jurriaans, et al.
AIDS Research and Human Retroviruses|October 29, 2000
Evaluation of a second-generation nucleic acid sequence-based amplification assay for quantification of HIV type 1 RNA and the use of ultrasensitive protocol adaptationsD W Notermans, F de Wolf, P Oudshoorn, et al.
The Journal of Infectious Diseases|March 9, 1999
Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected personsF W Wit, R van Leeuwen, G J Weverling, et al.
Antiviral Therapy|August 9, 2001
A dose-ranging study to evaluate the antiretroviral activity and safety of amprenavir alone and in combination with abacavir in HIV-infected adults with limited antiretroviral experienceR T Schooley, N Clumeck, R Haubrich, et al.
Science (New York, N.Y.)|May 9, 1997
Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infectionW Cavert, D W Notermans, K Staskus, et al.
AIDS (London, England)|June 15, 2000
The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individualsR P van Heeswijk, A I Veldkamp, J W Mulder, et al.
Pageof 13